Total hip arthroplasty with rehabilitation improves WOMAC and HHS scores versus conservative exercise in hip osteoarthritis
This single-centre randomized controlled trial evaluated 120 patients with moderate-to-severe hip osteoarthritis, defined as Kellgren-Lawrence grades 2 to 4. The intervention group received total hip arthroplasty combined with postoperative rehabilitation, while the comparator group underwent conservative treatment with a self-directed exercise programme. The primary outcomes assessed changes in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and the Harris Hip Score (HHS) at 12 months. Secondary outcomes included WOMAC at six months, WOMAC subscales, health-related quality of life domains from the RAND-36, and physical performance tests.
At 12 months, the WOMAC total score improved by 30.9 points in the THA group versus 3.7 points in the conservative group, yielding an effect size of 27.1 points with a 95% CI of -32.4 to -21.8. The HHS score increased by 29.8 points in the THA group compared to 5.7 points in the conservative group, with an effect size of 24.1 points and a 95% CI of 19.6 to 28.7. These results indicate significantly greater improvements in the THA group for both primary metrics.
Regarding conversion to surgery, 23 participants in the conservative group underwent THA, representing 38% of the 120 total participants. In the THA group, 2 participants declined to proceed with surgery. Superior gains were observed across all performance-based tests and most RAND-36 domains for the THA group. Safety data regarding adverse events and serious adverse events were not reported in the study.
The study limitations include its single-centre design and the lack of reported adverse events or tolerability data. Despite these constraints, the evidence supports that THA combined with postoperative rehabilitation provides clinically meaningful improvements in pain, function, and health-related quality of life compared with a self-directed exercise programme alone. THA is reinforced as the preferred option for eligible patients based on these findings.